IN8BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(In thousands, except share and per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $10,211 | $16,962 |
| General and administrative | 9,650 | 12,637 |
| Severance and related charges | — | 1,068 |
| Total operating expenses | 19,861 | 30,667 |
| Interest income | 421 | 230 |
| Loss from operations | (19,440) | (30,437) |
| Net loss | $(19,440) | $(30,437) |
| Net loss per share – basic and diluted | $(4.44) | $(17.05) |
| Weighted-average number of shares used in computing net loss per common share – basic and diluted(1) | 4,374,328 | 1,784,890 |
(1)All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.